1. Home
  2. BIIB vs NMR Comparison

BIIB vs NMR Comparison

Compare BIIB & NMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BIIB
  • NMR
  • Stock Information
  • Founded
  • BIIB 1978
  • NMR 1925
  • Country
  • BIIB United States
  • NMR Japan
  • Employees
  • BIIB N/A
  • NMR N/A
  • Industry
  • BIIB Biotechnology: Pharmaceutical Preparations
  • NMR Investment Bankers/Brokers/Service
  • Sector
  • BIIB Health Care
  • NMR Finance
  • Exchange
  • BIIB Nasdaq
  • NMR Nasdaq
  • Market Cap
  • BIIB 18.7B
  • NMR 19.5B
  • IPO Year
  • BIIB 1991
  • NMR 1961
  • Fundamental
  • Price
  • BIIB $127.70
  • NMR $6.96
  • Analyst Decision
  • BIIB Buy
  • NMR Hold
  • Analyst Count
  • BIIB 27
  • NMR 1
  • Target Price
  • BIIB $187.96
  • NMR N/A
  • AVG Volume (30 Days)
  • BIIB 1.5M
  • NMR 569.0K
  • Earning Date
  • BIIB 07-31-2025
  • NMR 07-29-2025
  • Dividend Yield
  • BIIB N/A
  • NMR 4.65%
  • EPS Growth
  • BIIB 31.67
  • NMR 81.67
  • EPS
  • BIIB 10.45
  • NMR 0.85
  • Revenue
  • BIIB $9,997,000,000.00
  • NMR $13,594,486,115.00
  • Revenue This Year
  • BIIB N/A
  • NMR N/A
  • Revenue Next Year
  • BIIB N/A
  • NMR N/A
  • P/E Ratio
  • BIIB $12.22
  • NMR $7.76
  • Revenue Growth
  • BIIB 3.36
  • NMR 17.62
  • 52 Week Low
  • BIIB $110.04
  • NMR $4.86
  • 52 Week High
  • BIIB $207.59
  • NMR $7.20
  • Technical
  • Relative Strength Index (RSI)
  • BIIB 46.35
  • NMR 63.82
  • Support Level
  • BIIB $124.56
  • NMR $6.59
  • Resistance Level
  • BIIB $134.16
  • NMR $7.20
  • Average True Range (ATR)
  • BIIB 3.98
  • NMR 0.12
  • MACD
  • BIIB -0.02
  • NMR 0.01
  • Stochastic Oscillator
  • BIIB 46.23
  • NMR 75.25

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

About NMR Nomura Holdings Inc ADR

Nomura Holdings Inc is a financial services group in Japan and operates offices in countries and regions world-wide, including Japan, the U.S., the U.K., Singapore, and the Hong Kong Special Administrative Region ("Hong Kong") through its subsidiaries. The company's clients include individuals, corporations, financial institutions, governments, and governmental agencies. The company's business consists of Wealth Management*, Investment Management, and Wholesale. The company generates the majority of its revenue from the wholesale segment. The Wholesale Division consists of two businesses, Global Markets, which is mainly engaged in the trading, sales, and structuring of financial products, and Investment Banking, which is engaged in advisory, financing, and solutions businesses.

Share on Social Networks: